Modus Outcomes

An international consultancy providing services to measure the benefit and clinical value of medical products using clinical outcome assessments.

[Modus Outcomes @ModusOutcomes]

Our findings highlight the importance of matching context-of-use to concept-of-interest, and will help inform future studies.

#Lupus #PatientCenteredOutcomes

[Modus Outcomes @ModusOutcomes]

People affected by #SLE commonly report #fatigue. This means it is vital that pivotal clinical trials include #PRO instruments that adequately measure this cardinal symptom.

[Modus Outcomes @ModusOutcomes]

In our recently published co-authored Open Access paper, we present #ConceptDrivenMeasurement analyses of clinical trial data, including legacy fatigue PROs: https://t.co/IY0M9PswNn

[Modus Outcomes @ModusOutcomes]

At #EHA2021, @ModusOutcomes is presenting a landscape review, which includes a series of graphical displays, applied to real clinical trial data, to illustrate how #PROCTCAE data can be used to gain a better understanding of the patient experience of symptomatic toxicities.

[Modus Outcomes @ModusOutcomes]

At #MADID2021, @ModusOutcomes will present the findings of a qualitative study, conducted in partnership with @Regeneron, considering the heretofore unexplored symptoms and daily life impacts of #COVID19 on outpatients.

#PatientCenteredOutcomes #QualitativeResearch

[Modus Outcomes @ModusOutcomes]

This research provides an evidence base to inform patient-centered outcome benefit demonstration in future clinical trials in this cancer.

#PatientExperience #RareCancer #ISPORAnnual #Oncology

[Modus Outcomes @ModusOutcomes]

#NUTCarcinoma is a rare, highly aggressive cancer, in which little is known about the patient experience. At Virtual @ISPORorg 2021, @ModusOutcomes is presenting a qualitative research study which aimed to better understand the symptoms and impact of NUT Carcinoma on patients.

[Modus Outcomes @ModusOutcomes]

For more information, please contact Melody Bauer at [email protected].

#RareDisease #PatientCenteredOutcomeMeasures #ClinicalOutcomeAssessments

[Modus Outcomes @ModusOutcomes]

The rare disease treatment trial session was a highlight of this week’s @CPathInstitute PRO Consortium Workshop. If you are interested in getting on track with your PCO strategy, you may be interested in our co-authored paper with @DrThomasMorel: https://t.co/Jq4Z5MjrWx

[Modus Outcomes @ModusOutcomes]

Interested in Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA) clinical trials and patient-centered outcome measures? Please see our Spotlight On: https://t.co/AL6AeY5lV4

#PatientCenteredOutcomes #ClinicalTrials #Duchenne #SpinalMuscularAtrophy

[Modus Outcomes @ModusOutcomes]

Interested in learning more about the interpretation and meaning of patient-reported outcome results? Here is Part 3 of 4 of @ModusOutcomes Q&A session on our reflections of the @FDAcdrhIndustry's Virtual Public Meeting held in the Fall 2020: https://t.co/8huGF8QehX

#PROs #MDDT

[Modus Outcomes @ModusOutcomes]

This global research initiative will contribute to improving the design and interpretation of statistical analyses of patient-reported outcome endpoints of clinical trials of new cancer-focused therapies.

#CancerResearch #PRO #ThoroughYetUseful

[Modus Outcomes @ModusOutcomes]

@ModusOutcomes is proud to be an official member of the @SISAQOL-IMI consortium made up of key stakeholders representing industry, academia, non-profit associations, cancer institutes, regulators, and patient advocacy organizations.

https://t.co/vE2pXxrVvb

[Modus Outcomes @ModusOutcomes]

Interested in the use of Patient Reported Outcomes in Medical Device Evaluation? Here is Part 1 of 4 of @ModusOutcomes Q&A session on our reflections of the @FDAcdrhIndustry’s Virtual Public Meeting held in the Fall 2020: https://t.co/ZONuf5FVct

#PROs #MedicalDevice #MDDT

[Modus Outcomes @ModusOutcomes]

Best wishes for 2021 from the @ModusOutcomes team! Thank you for a productive 2020. We look forward to continuing to work with you in the new year to measure what matters to patients.

https://t.co/DhTXXMlqGf

#HappyNewYear #PatientCenteredOutcomes #ConceptDrivenMeasurement

[Modus Outcomes @ModusOutcomes]

@ModusOutcomes will present two posters on the #PRO results of two hematological cancer clinical trials conducted with @GSK and @TakedaPharma at the 62nd @ASH_hematology Annual Meeting and Exposition taking place on December 5-8.

Register now for #ASH20: https://t.co/vxSNagAgux

[Modus Outcomes @ModusOutcomes]

Registration details for Session 5: Multi-Stakeholder Perspectives on Value and Future of PROs in Clinical Trials (December 4, 14:00-16:30 CET), chaired by @DrThomasMorel, can be found here: https://t.co/gU6hNTIFHY

#ModusOutcomes #PatientReportedOutcomes #GoodEnoughIsNotEnough

[Modus Outcomes @ModusOutcomes]

@ModusOutcomes' @A_Regnault_PhD will outline in a multi-stakeholder session at @DrugInfoAssn's Advancing Patient Science Workshop how concept-driven measurement and mixed methods research can increase the value of PROs in clinical trials and healthcare decision-making.

[Modus Outcomes @ModusOutcomes]

Catch @A_Regnault_PhD and Juliette Meunier this afternoon as they present their research for @biogen on the interpretation of PerfO at the #ISOQOL Cutting Edge Research Plenary.

Learn more here: https://t.co/eamLjZpAJQ

#ThoroughYetUseful

[Modus Outcomes @ModusOutcomes]

This year's @ISOQOL is an opportunity for @ModusOutcomes to showcase our commitment to unlock methodological challenges and help our clients in their high-stakes decisions.

#InsatiableCuriosity